REGENERON PHARMACEUTICALS
#753 COMPANY RANKING
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Since 1988
Claim This Company
#753
Ranking Index(All Ranking)0%
Grow & Performance(seo & stats)0
Traffic(Website traffic, unique visiotrs & user retention)- Company Ranking
- Stock Price
REGENERON PHARMACEUTICALS (REGN)
5D1M6Mmax
EVERGREEN INDEX #753
Regeneron Pharmaceuticals's stories on HackerNoon
Technology evolves every day, impacting our lives more and more. Don’t miss out on the tech of tomorrow via these remarkable technology stories.
4 Potential Drug Treatment Options to Battle This Outbreak of Coronavirus
Sat Mar 21 2020 By Linda Willemse
Regeneron Pharmaceuticals's latest news & mentions
Explore a rich selection of stories about your favorite games, how they are made, and the people that make them, from gamers and game developers worldwide.
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm
nypost.com
Fri Jun 13 2025
23andMe to delist from Nasdaq, deregister with SEC
cnbc.com
Tue May 27 2025
Regeneron buys 23andMe for $256 million amid bankruptcy
wltx.com
Mon May 19 2025
23andMe Has a Buyer -and Privacy Concerns
newser.com
Mon May 19 2025
23andMe sells gene-testing business to DNA drug maker Regeneron
latimes.com
Mon May 19 2025
Regeneron Pharmaceuticals to buy 23andMe -- and its genetic data -- for $256 million
nypost.com
Mon May 19 2025
Biotechnology company Regeneron buying bankrupt 23andMe for $256M
abc7.com
Mon May 19 2025
Regeneron Pharmaceuticals to pay $256 million for 23andMe in bankruptcy sale
upi.com
Mon May 19 2025
Bankrupt DNA testing firm 23andMe to be purchased for $256m
theguardian.com
Mon May 19 2025
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
cnbc.com
Mon May 19 2025
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
finance.yahoo.com
Thu Jan 02 2025
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts
markets.businessinsider.com
Tue Jun 25 2024
Regeneron Pharmaceuticals's Related Companies
Explore a rich selection of stories about your favorite games, how they are made, and the people that make them, from gamers and game developers worldwide.Barnebys
barnebys.com
#10669 RANK
Founded2011
THE COTTON-BEES by Jean-Henri Fabre
MAENCK BLUNDERS by Edgar Rice Burroughs
Biolytica
biolytica.com
#10330 RANK
Founded2021
Byju's
byjus.com
#3699 RANK
Founded2011
What Investors Want From AI Startups in 2025 by susie liu
A Melancholic Encounter in Folkestone by H.G. Wells
COVALYZE
covalyze.com
#8555 RANK
Founded2019
EliseAI
eliseai.com
#7810 RANK
Founded2017
A TALE OF THE PASSIONS; OR, THE DEATH OF DESPINA by Mary Wollstonecraft Shelley
FansForX
fansforx.com
#9528 RANK
Founded